S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.78 (+0.52%)
AMD   202.64 (+5.25%)
BABA   74.62 (+0.80%)
T   16.98 (+0.30%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.65 (+1.12%)
DIS   111.95 (+0.33%)
AMC   4.36 (+0.93%)
PFE   26.59 (+0.11%)
PYPL   60.54 (+0.33%)
XOM   105.84 (+1.26%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.78 (+0.52%)
AMD   202.64 (+5.25%)
BABA   74.62 (+0.80%)
T   16.98 (+0.30%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.65 (+1.12%)
DIS   111.95 (+0.33%)
AMC   4.36 (+0.93%)
PFE   26.59 (+0.11%)
PYPL   60.54 (+0.33%)
XOM   105.84 (+1.26%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.78 (+0.52%)
AMD   202.64 (+5.25%)
BABA   74.62 (+0.80%)
T   16.98 (+0.30%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.65 (+1.12%)
DIS   111.95 (+0.33%)
AMC   4.36 (+0.93%)
PFE   26.59 (+0.11%)
PYPL   60.54 (+0.33%)
XOM   105.84 (+1.26%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.78 (+0.52%)
AMD   202.64 (+5.25%)
BABA   74.62 (+0.80%)
T   16.98 (+0.30%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.65 (+1.12%)
DIS   111.95 (+0.33%)
AMC   4.36 (+0.93%)
PFE   26.59 (+0.11%)
PYPL   60.54 (+0.33%)
XOM   105.84 (+1.26%)

Neurocrine Biosciences (NBIX) Short Interest Ratio & Short Volume

$131.30
+0.90 (+0.69%)
(As of 05:24 PM ET)

Neurocrine Biosciences Short Interest Data

Current Short Volume
2,180,000 shares
Previous Short Volume
1,880,000 shares
Change Vs. Previous Month
+15.96%
Dollar Volume Sold Short
$292.12 million
Short Interest Ratio / Days to Cover
2.7
Last Record Date
February 15, 2024
Outstanding Shares
99,507,000 shares
Percentage of Shares Shorted
2.19%
Today's Trading Volume
1,322,126 shares
Average Trading Volume
828,098 shares
Today's Volume Vs. Average
160%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Neurocrine Biosciences ?

Sign up to receive the latest short interest report for Neurocrine Biosciences and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

NBIX Short Interest Over Time

NBIX Days to Cover Over Time

NBIX Percentage of Float Shorted Over Time


Neurocrine Biosciences Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
2/15/20242,180,000 shares $292.12 million +16.0%N/A2.7 $134.00
1/31/20241,880,000 shares $262.77 million -18.6%N/A2.4 $139.77
1/15/20242,310,000 shares $304.99 million +1.8%N/A3.1 $132.03
12/31/20232,270,000 shares $299.10 million -0.4%N/A3.2 $131.76
12/15/20232,280,000 shares $274.10 million +8.1%N/A3.2 $120.22
11/30/20232,110,000 shares $246.00 million -7.5%N/A3.1 $116.59
11/15/20232,280,000 shares $252.42 million +2.2%N/A3.4 $110.71
10/31/20232,230,000 shares $247.40 million +1.8%N/A3.4 $110.94
10/15/20232,190,000 shares $247.12 million +18.4%N/A3.2 $112.84
9/30/20231,850,000 shares $208.13 million -8.4%N/A2.6 $112.50
9/15/20232,020,000 shares $227.15 million No ChangeN/A2.8 $112.45
8/31/20232,020,000 shares $219.96 million +3.6%N/A2.6 $108.89
8/15/20231,950,000 shares $207.32 million -3.9%N/A2.6 $106.32
7/31/20232,030,000 shares $206.84 million -12.9%N/A2.7 $101.89
7/15/20232,330,000 shares $221.61 million -3.7%N/A3.1 $95.11
6/30/20232,420,000 shares $228.21 million -5.1%N/A3.3 $94.30
6/15/20232,550,000 shares $246.97 million -1.9%N/A3.5 $96.85
5/31/20232,600,000 shares $232.78 million -6.8%N/A3.7 $89.53
5/15/20232,790,000 shares $273.84 million +5.7%N/A4 $98.15
4/30/20232,640,000 shares $266.75 million +3.5%N/A3.5 $101.04
4/15/20232,550,000 shares $262.09 million -7.6%N/A3.4 $102.78
3/31/20232,760,000 shares $279.37 million +3.4%N/A3.4 $101.22
3/15/20232,670,000 shares $251.27 million +5.1%N/A3.4 $94.11
2/28/20232,540,000 shares $261.87 million -1.6%N/A3.2 $103.10
2/15/20232,580,000 shares $267.62 million -1.2%N/A3.3 $103.73
1/31/20232,610,000 shares $289.53 million +0.8%2.8%3.2 $110.93
1/15/20232,590,000 shares $282.28 million +15.1%2.8%3.2 $108.99
12/30/20222,250,000 shares $268.74 million +0.5%2.4%2.8 $119.44
12/15/20222,240,000 shares $261.39 million -16.7%2.4%2.7 $116.69
11/30/20222,690,000 shares $341.79 million -5.3%2.9%3.3 $127.06
11/15/20222,840,000 shares $325.95 million +8.0%3.0%3.5 $114.77
10/31/20222,630,000 shares $302.77 million -4.0%2.8%3.3 $115.12
10/15/20222,740,000 shares $296.55 million +3.0%2.9%3.6 $108.23
9/30/20222,660,000 shares $282.52 million +10.4%2.8%3.6 $106.21
9/15/20222,410,000 shares $257.70 million +11.6%2.6%3.4 $106.93
8/31/20222,160,000 shares $226.00 million -21.7%2.3%3 $104.63
8/15/20222,760,000 shares $296.40 million +7.0%3.0%3.7 $107.39
7/31/20222,580,000 shares $242.86 million -0.8%2.8%3.3 $94.13
7/15/20222,600,000 shares $247.44 million +5.3%2.8%3.4 $95.17
6/30/20222,470,000 shares $240.78 million -33.8%2.6%3.2 $97.48













NBIX Short Interest - Frequently Asked Questions

What is Neurocrine Biosciences' current short interest?

Short interest is the volume of Neurocrine Biosciences shares that have been sold short but have not yet been covered or closed out. As of February 15th, traders have sold 2,180,000 shares of NBIX short. Learn More on Neurocrine Biosciences' current short interest.

What is a good short interest ratio for Neurocrine Biosciences?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. NBIX shares currently have a short interest ratio of 3.0. Learn More on Neurocrine Biosciences's short interest ratio.

Which institutional investors are shorting Neurocrine Biosciences?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Neurocrine Biosciences: GTS Securities LLC, Parallax Volatility Advisers L.P., Citadel Advisors LLC, PEAK6 Investments LLC, Concourse Financial Group Securities Inc., and Portman Square Capital LLP. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Is Neurocrine Biosciences' short interest increasing or decreasing?

Neurocrine Biosciences saw a increase in short interest in February. As of February 15th, there was short interest totaling 2,180,000 shares, an increase of 16.0% from the previous total of 1,880,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Neurocrine Biosciences' short interest compare to its competitors?

Here is how the short interest of companies in the sector of "medical" compare to Neurocrine Biosciences: Repligen Co. (10.29%), Halozyme Therapeutics, Inc. (6.10%), Denali Therapeutics Inc. (9.73%), Adaptive Biotechnologies Co. (6.35%), Biogen Inc. (2.15%), Bio-Techne Co. (3.01%), Qiagen (1.43%), CRISPR Therapeutics AG (18.52%), Immunovant, Inc. (14.84%), BioNTech SE (1.27%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Super Micro Computer, Inc. ($5.32 billion), T-Mobile US, Inc. ($4.38 billion), General Motors ($3.76 billion), Occidental Petroleum Co. ($3.08 billion), Charter Communications, Inc. ($2.65 billion), Coinbase Global, Inc. ($2.62 billion), Tractor Supply ($2.52 billion), Moderna, Inc. ($2.19 billion), Rivian Automotive, Inc. ($1.84 billion), and Royal Caribbean Cruises Ltd. ($1.78 billion). View all of the most shorted stocks.

What does it mean to sell short Neurocrine Biosciences stock?

Short selling NBIX is an investing strategy that aims to generate trading profit from Neurocrine Biosciences as its price is falling. NBIX shares are trading up $0.90 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Neurocrine Biosciences?

A short squeeze for Neurocrine Biosciences occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of NBIX, which in turn drives the price of the stock up even further.

How often is Neurocrine Biosciences' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NBIX, twice per month. The most recent reporting period available is February, 15 2024.



More Short Interest Resources from MarketBeat

This page (NASDAQ:NBIX) was last updated on 3/1/2024 by MarketBeat.com Staff